Navigation Links
Derma Sciences Inc Selects Allen & Caron for Investor Relations and Corporate Communications
Date:12/17/2007

PRINCETON, N.J., Dec. 17 /PRNewswire/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced that it has selected Allen & Caron, Inc. as its agency for investor relations and corporate communications.

"Derma Sciences is in a period of strong growth due in part to our recent acquisition of the first aid division of NutraMax, as well as the FDA clearance of our MEDIHONEY(TM) products, and the licensing of DSC127, a novel drug for wound healing and scar reduction. With the help of Allen & Caron, we are preparing to step up our communications outreach to the investment community," commented Edward J. Quilty, Chairman and CEO. "After a thorough review of several agencies, we chose Allen & Caron due to its solid reputation and history of increasing client profiles among institutional investors, which is an essential part of any plan to attract qualified investors. In addition I have worked with Allen & Caron in the past, and respect their work and their work ethic."

Allen & Caron Chairman and CEO Joe Allen, said "Advanced wound care has shifted from basic moisture management at the site of a wound, to more active therapies. Derma Sciences is well positioned as an innovator, with wound care products based on honey, on silver, and on other substances that promote healing without the use of antibiotics. We believe investors will see Derma Sciences as a deep value company, with a market cap that far lags its revenues, developing and launching interesting new products with essentially no burn rate. We believe they will see that it is at a flexion point where value and growth coincide, creating a compelling investment thesis."

Aside from its full lines of advanced and traditional wound care products, Derma Sciences continues to develop and commercialize key products such as MEDIHONEY(TM), MOBILITY1(TM) and ALGICELL(TM)Ag. MEDIHONEY(TM) is the first honey-based product cleared by the FDA for wound and burn management. MOBILITY1(TM) is a patented novel intermittent pneumatic compression (IPC) therapy device which delivers segmented and gradient pressure to the lower legs of ambulatory and/or stationary patients. ALGICELL(TM)Ag is a best-in-class antimicrobial silver alginate product.

With wholly owned and operated manufacturing facilities in Toronto and Nantong, China, Derma Sciences also offers state-of-the-art contract manufacturing services for OEM or private label products. The Company's goal is to increase their leadership position in the growing field of wound and skin care, leveraging their key brands as well as their manufacturing capabilities, while bringing next-generation products and technologies to market.

About Allen & Caron

Allen & Caron is a full-service corporate, investor and marketing communications agency serving the needs of public companies. The Allen & Caron international client base includes emerging growth companies in a range of industry segments. The firm has offices in Irvine, California; New York City; and London; maintains a presence in Paris; and has an affiliate relationship with a leading investor relations firm in Italy.

About Derma Sciences

Derma Sciences is a manufacturer and marketer of advanced wound care products, with operations based in the US and Canada, and sales worldwide. The company sources Active Manuka (Leptospermum scoparium) Honey from Comvita New Zealand, Ltd. Comvita controls over 70% of the flow of manuka honey, and owns several patents around the use of honey in wound dressings. The Company has also obtained FDA clearance to market and sell its MOBILITY-1(TM) boot and compressor device for the treatment of venous ulcers, lymphedema, and other conditions that require compression therapy. For more information about Derma Sciences Inc, visit its home page on the Internet at http://www.dermasciences.com.

Forward-looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned, that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.

Contact:

Allen & Caron Derma Sciences

(212) 691-8087 609-514-4744

Rudy Barrio (US Investors) Edward J. Quilty

r.barrio@allencaron.com Chairman and CEO

equilty@dermasciences.com


'/>"/>
SOURCE Allen & Caron, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
2. Dermatologists identify North Texas leishmaniasis outbreak
3. Tissue-Growth Gene Tied to Scleroderma
4. American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act
5. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
6. VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
7. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
8. American Academy of Dermatology: New Study Finds Women More Likely Than Men to be Affected by Acne as Adults
9. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
10. Dermatologists Warn Fitness Enthusiasts: Dont Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity
11. Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: